Skip to content
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
featured-image

AI healthcare platform

enterprise platform

From idea to c-suite buy-In: A framework for driving enterprise AI in healthcare

From idea to C-suite buy-in: how internal leaders can drive scalable AI adoption In a healthcare environment marked by capacity constraints, clinician burnout, and fiscal pressure, enterprise AI holds immense promise—but only if it can move beyond pilot programs and point solutions. The key to unlocking its full potential? Empowered internal champions who drive executive alignment to unleash the promise of AI across the system.
featured-image

Physician

AI

Advanced Imaging

Clinical Decision Support

AI healthcare platform

enterprise platform

Scaling AI from siloed tools to an enterprise platform

Artificial intelligence (AI) has the power to transform healthcare—but only if it can be scaled across the enterprise. In many systems today, AI exists in silos: one algorithm in radiology, another in the ED, and a third in population health. The result? Fragmented workflows, inconsistent ROI, and missed opportunities to improve patient care. To move from isolated tools to a true enterprise platform, healthcare leaders must take a strategic, integrated approach to scaling AI.
featured-image

Stroke

AI

The Impact of Automated Software on Alberta Stroke Program Early CT Score

The Alberta Stroke Program Early CT Score (ASPECTS) is essential for clinical decision-making when treating ischemic stroke patients. It helps measure early ischemic changes and predict the functional outcome of endovascular thrombectomy.
featured-image

Aneurysm

AI

Advanced Imaging

Funding brain aneurysm research: Q&A with Christine Buckley of the Brain Aneurysm Foundation

RapidAI is proud to partner with the Brain Aneurysm Foundation (BAF) and support its mission to promote early detection of brain aneurysms by raising awareness of the signs, symptoms, and risk factors.
featured-image

Stroke

AI

Advanced Imaging

Neurovascular imaging for patients with suspected transient ischemic attack

Approximately 240,000 people in the United States experience a transient ischemic attack (TIA) annually. A TIA is a stroke lasting only a few minutes when the blood supply to part of the brain is briefly interrupted.
featured-image

Stroke

Workflow

AI

Mastering the Art of Patient Transfer: Utilizing RapidAI Software for Seamlessly Transferring Patients to a Different Hospital

Neuroimaging has played a significant role in the stroke workflow following the DAWN and DEFUSE 3 trials and revised guidelines for acute ischemic stroke treatment. It helps determine which patients are eligible for endovascular thrombectomy (EVT) in the late window.
featured-image

Stroke

AI

Advanced Imaging

Optimal patient selection for endovascular thrombectomy procedure: CT Perfusion versus Non-contrast CT

Landmark stroke clinical trials DAWN and DEFUSE 3 helped validate the benefits of endovascular thrombectomy (EVT) procedure in acute ischemic stroke patients (AIS) in the late window. CT perfusion (CTP) aided in selecting eligible patients with a favorable perfusion profile.
featured-image

Stroke

AI

Neuroprotectant ApTOLL reduced death and disability in acute ischemic stroke patients

ApTOLL, a neuroprotective agent, has shown promising results in the APRIL 1b/2a trial and reduced death and disability when used alongside standard treatment in selected ischemic stroke patients. Rapid CTP helped with patient selection and mismatch determination.
featured-image

Stroke

Workflow

Advanced Imaging

Intracranial hemorrhage management with Rapid software

Rapid ICH 3.0 and Rapid Hyperdensity represent the best-in-class hemorrhagic solutions supporting clinicians managing intracranial hemorrhage (both hemorrhagic stroke and head trauma). Two studies presented at the International Stroke Conference (ISC) 2023 provide further clinical evidence of the value of these technologies.
1 2 3